See more : Vicinity Centres (CNRAF) Income Statement Analysis – Financial Results
Complete financial analysis of MorphoSys AG (MOR.SW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MorphoSys AG, a leading company in the Biotechnology industry within the Healthcare sector.
- Solaer Renewable Energies Ltd (SOLR.TA) Income Statement Analysis – Financial Results
- Nishio Rent All Co., Ltd. (9699.T) Income Statement Analysis – Financial Results
- Hong Kong Technology Venture Company Limited (1137.HK) Income Statement Analysis – Financial Results
- REE Automotive Ltd. (REEAW) Income Statement Analysis – Financial Results
- Eugene Investment & Securities Co.,Ltd. (001200.KS) Income Statement Analysis – Financial Results
MorphoSys AG (MOR.SW)
About MorphoSys AG
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 238.28M | 278.27M | 179.60M | 327.70M | 71.76M | 76.44M | 66.79M | 49.74M | 106.22M | 63.98M | 77.96M | 51.92M | 100.78M | 87.04M | 81.02M | 71.65M | 61.96M | 53.03M | 7.98M | 21.98M | 15.31M | 16.76M |
| Cost of Revenue | 58.36M | 48.62M | 32.20M | 9.17M | 12.09M | 1.80M | 33.00K | 97.00K | 77.00K | 77.00K | 29.00K | 0.00 | 7.02M | 7.28M | 6.74M | 7.14M | -7.95M | -7.98M | -2.51M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 179.92M | 229.65M | 147.40M | 318.52M | 59.67M | 74.65M | 66.76M | 49.65M | 106.15M | 63.90M | 77.93M | 51.92M | 93.75M | 79.75M | 74.28M | 64.51M | 69.91M | 61.01M | 10.49M | 21.98M | 15.31M | 16.76M |
| Gross Profit Ratio | 75.51% | 82.53% | 82.07% | 97.20% | 83.16% | 97.65% | 99.95% | 99.80% | 99.93% | 99.88% | 99.96% | 100.00% | 93.03% | 91.63% | 91.68% | 90.04% | 112.83% | 115.05% | 131.51% | 100.00% | 100.00% | 100.00% |
| Research & Development | 283.61M | 297.81M | 225.20M | 141.43M | 108.43M | 106.40M | 116.81M | 95.72M | 78.66M | 55.96M | 49.15M | 37.67M | 57.48M | 46.90M | 38.97M | 27.60M | -22.24M | -17.46M | -14.03M | 12.39M | 9.00M | 19.59M |
| General & Administrative | 86.22M | 83.90M | 78.30M | 51.40M | 36.66M | 21.93M | 12.32M | 9.52M | 10.35M | 9.61M | 11.28M | 12.08M | 24.58M | 23.23M | 23.91M | 20.48M | 0.00 | -21.42M | -10.07M | 7.52M | 7.60M | 18.74M |
| Selling & Marketing | 6.32M | 6.33M | 121.50M | 107.74M | 22.67M | 6.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 92.54M | 90.23M | 199.80M | 159.15M | 59.34M | 28.31M | 12.32M | 9.52M | 10.35M | 9.61M | 11.28M | 12.08M | 24.58M | 23.23M | 23.91M | 20.48M | 0.00 | -21.42M | -10.07M | 7.52M | 7.60M | 18.74M |
| Other Expenses | 968.00K | 62.32M | 1.80M | 9.41M | 178.06K | 79.00K | 5.29M | 4.30M | 4.37M | 4.23M | 7.56M | -258.00K | -466.27K | -222.42K | 0.00 | 0.00 | 0.00 | 17.46M | -710.44K | 1.42M | 2.18M | 3.94M |
| Operating Expenses | 430.78M | 450.36M | 425.00M | 300.57M | 167.77M | 134.79M | 134.41M | 109.55M | 93.38M | 69.80M | 68.00M | 49.50M | 81.60M | 69.90M | 62.88M | 48.08M | -22.24M | -21.42M | -24.81M | 21.34M | 18.77M | 42.28M |
| Cost & Expenses | 489.14M | 498.98M | 457.20M | 309.75M | 179.85M | 136.58M | 134.44M | 109.64M | 93.45M | 69.88M | 68.03M | 49.50M | 88.62M | 77.19M | 69.62M | 55.22M | -30.18M | -29.40M | -27.33M | 21.34M | 18.77M | 42.28M |
| Interest Income | 18.32M | 4.62M | 96.60M | 92.05M | 2.80M | 91.00K | 236.00K | 1.02M | 1.91M | 1.00M | 347.00K | 178.00K | 1.44M | 4.12M | 0.00 | 1.49M | 0.00 | 0.00 | 0.00 | 624.16K | 1.09M | 446.55K |
| Interest Expense | 109.86M | 116.52M | 181.50M | 96.21M | 2.27M | 179.00K | 374.00K | 20.00K | 20.00K | 118.00K | 22.00K | 8.00K | 27.27K | 33.88K | 9.54K | 6.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 10.54M | 10.54M | 98.40M | 8.33M | 6.25M | 3.75M | 4.03M | 3.76M | 3.45M | 4.13M | 4.83M | 6.31M | 6.63M | 6.12M | 5.35M | 5.24M | 5.19M | 4.95M | 3.62M | 2.64M | 2.49M | 2.13M |
| EBITDA | -235.42M | -205.93M | -269.90M | 127.74M | -98.87M | -56.55M | -64.39M | -56.08M | 24.10M | -56.22K | 15.52M | 8.95M | 18.09M | 19.33M | 18.39M | 23.23M | 16.67M | 10.24M | 7.87M | 2.92M | -976.45K | -23.39M |
| EBITDA Ratio | -41.02% | 62.10% | -99.78% | 38.98% | -137.79% | -73.97% | -96.40% | -112.74% | 22.69% | -0.09% | 27.56% | 17.23% | 17.95% | 22.20% | 22.70% | 32.42% | 26.90% | 19.30% | 98.58% | 13.28% | -10.83% | -132.89% |
| Operating Income | -252.48M | 162.26M | -277.60M | 119.41M | -105.12M | -60.14M | -67.65M | -59.90M | 12.77M | -5.90M | 9.93M | 2.42M | 12.16M | 9.85M | 11.40M | 16.42M | 92.15M | 82.43M | 35.31M | 641.41K | -3.47M | -25.52M |
| Operating Income Ratio | -105.96% | 58.31% | -154.57% | 36.44% | -146.50% | -78.67% | -101.29% | -120.42% | 12.02% | -9.23% | 12.74% | 4.66% | 12.06% | 11.32% | 14.07% | 22.92% | 148.71% | 155.43% | 442.50% | 2.92% | -22.64% | -152.28% |
| Total Other Income/Expenses | 61.55M | 238.23M | -313.50M | 4.54M | -71.84K | -19.60M | -11.60M | -9.91M | 7.86M | -2.30M | -981.01K | 633.00K | -727.52K | 3.32M | 1.63M | 1.56M | 0.00 | -77.14M | -30.19M | -359.29K | -681.96K | 1.16M |
| Income Before Tax | -190.92M | 17.52M | -591.10M | 22.49M | -106.52M | -60.48M | -68.79M | -59.86M | 20.63M | -4.31M | 10.68M | 3.05M | 11.43M | 13.17M | 13.03M | 17.99M | 0.00 | 5.29M | 5.11M | 282.11K | -4.15M | -24.36M |
| Income Before Tax Ratio | -80.13% | 6.30% | -329.12% | 6.86% | -148.45% | -79.11% | -102.99% | -120.34% | 19.42% | -6.73% | 13.70% | 5.88% | 11.34% | 15.13% | 16.09% | 25.10% | 0.00% | 9.97% | 64.07% | 1.28% | -27.10% | -145.37% |
| Income Tax Expense | -1.19M | 168.58M | -76.60M | -75.40M | -3.51M | -4.30M | 1.04M | 518.63K | 5.72M | -1.30M | 3.31M | 685.81K | 3.21M | 3.98M | 4.07M | 4.83M | 0.00 | -742.06K | -435.59K | -359.29K | -21.00 | -18.08K |
| Net Income | -189.73M | -151.06M | -514.50M | 97.89M | -103.01M | -56.17M | -69.83M | -60.38M | 14.90M | -3.01M | 13.32M | 1.94M | 8.22M | 9.20M | 8.96M | 13.15M | 11.47M | 6.03M | 4.68M | 282.11K | -4.15M | -24.38M |
| Net Income Ratio | -79.63% | -54.29% | -286.47% | 29.87% | -143.56% | -73.48% | -104.54% | -121.39% | 14.03% | -4.71% | 17.09% | 3.74% | 8.15% | 10.57% | 11.06% | 18.36% | 18.52% | 11.37% | 58.61% | 1.28% | -27.10% | -145.47% |
| EPS | -5.53 | -4.52 | -15.40 | 3.01 | -3.26 | -1.79 | -2.41 | -2.28 | 0.57 | -0.12 | 0.54 | 0.08 | 0.36 | 0.41 | 0.40 | 0.59 | 0.60 | 0.31 | 0.28 | 0.02 | -0.32 | -2.12 |
| EPS Diluted | -5.53 | -4.52 | -15.40 | 2.97 | -3.26 | -1.79 | -2.41 | -2.27 | 0.57 | -0.12 | 0.54 | 0.08 | 0.36 | 0.40 | 0.40 | 0.59 | 0.60 | 0.31 | 0.27 | 0.02 | -0.32 | -2.12 |
| Weighted Avg Shares Out | 34.31M | 33.41M | 33.40M | 32.53M | 31.61M | 31.34M | 28.95M | 26.44M | 26.02M | 25.90M | 24.50M | 23.00M | 22.89M | 22.66M | 22.46M | 22.22M | 19.14M | 19.14M | 16.74M | 15.39M | 13.00M | 11.52M |
| Weighted Avg Shares Out (Dil) | 34.31M | 33.41M | 33.41M | 33.17M | 31.61M | 31.34M | 28.95M | 26.54M | 26.24M | 26.19M | 24.76M | 23.26M | 23.13M | 22.79M | 22.56M | 22.33M | 19.14M | 19.14M | 17.32M | 15.39M | 13.00M | 11.52M |
Source: https://incomestatements.info
Category: Stock Reports